AI Article Synopsis
- The study investigates the rise in narcolepsy type 1 (NT1) cases in Sweden after the 2009-2010 Pandemrix influenza vaccination, linking it to specific genetic markers (HLA alleles).
- Analysis of 31 NT1 patients and 66 of their relatives revealed a strong association between NT1 and a specific HLA haplotype, primarily involving the DQB1*06:02:01 allele, found in 96.8% of patients.
- The research underscores the value of high-resolution HLA typing in understanding the immunological factors contributing to vaccine-related NT1 cases and identifies additional haplotypes that may influence the condition.
Article Abstract
The incidence of narcolepsy type 1 (NT1) increased in Sweden following the 2009-2010 mass-vaccination with the influenza Pandemrix-vaccine. NT1 has been associated with Human leukocyte antigen (HLA) DQB1*06:02 but full high-resolution HLA-typing of all loci in vaccine-induced NT1 remains to be done. Therefore, here we performed HLA typing by sequencing HLA-DRB3, DRB4, DRB5, DRB1, DQA1, DQB1, DPA1 and DPB1 in 31 vaccine-associated NT1 patients and 66 of their first-degree relatives (FDR), and compared these data to 636 Swedish general population controls (GP). Previously reported disease-related alleles in the HLA-DRB5*01:01:01-DRB1*15:01:01-DQA1*01:02:01-DQB1*06:02:01 extended haplotype were increased in NT1 patients (34/62 haplotypes, 54.8%) compared to GP (194/1272 haplotypes, 15.3%, p = 6.17E-16). Indeed, this extended haplotype was found in 30/31 patients (96.8%) and 178/636 GP (28.0%). In total, 15 alleles, four extended haplotypes, and six genotypes were found to be increased or decreased in frequency among NT1 patients compared to GP. Among subjects with the HLA-DRB5*01:01:01-DRB1*15:01:01-DQA1*01:02-DQB1*06:02 haplotype, a second DRB4*01:03:01-DRB1*04:01:01-DQA1*03:02//*03:03:01-DQB1*03:01:01 haplotype (p = 2.02E-2), but not homozygosity for DRB1*15:01:01-DQB1*06:02:01 (p = 7.49E-1) conferred association to NT1. Alleles with increased frequency in DQA1*01:02:01 (p = 1.07E-2) and DQA1*03:02//*03:03:01 (p = 3.26E-2), as well as with decreased frequency in DRB3*01:01:02 (p = 8.09E-3), DRB1*03:01:01 (p = 1.40E-2), and DQB1*02:01:01 (p = 1.40E-2) were found among patients compared to their FDR. High-resolution HLA sequencing in Pandemrix-associated NT1 confirmed the strong association with the DQB1*06:02:01-containing haplotype but also revealed an increased association to the not previously reported extended HLA-DRB4*01:03:01-DRB1*04:01:01-DQA1*03:02//*03:03:01-DQB1*03:01:01 haplotype. High-resolution HLA typing should prove useful in dissecting the immunological mechanisms of vaccination-associated NT1.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6774514 | PMC |
| http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0222882 | PLOS |
Publication Analysis
Top Keywords
Similar Publications
Z hypnotics in the management of narcolepsy: a case series.
J Clin Sleep Med
December 2024
Sleep Disorders & Research Center, Department of Sleep Medicine, Henry Ford Health System, Detroit, MI.
Study Objectives: Here we report our experience treating patients with narcolepsy using benzodiazepine receptor agonists (BzRA), zolpidem (Zol) or eszopiclone (Esz) taken at bedtime for both excessive daytime sleepiness (EDS) and cataplexy.
Methods: We reviewed the medical records of 53 patients diagnosed with narcolepsy, between 2002 and 2023. Twenty-three patients, 8 with type1 (NT1), 13 with type 2 (NT2) and 2 with secondary narcolepsy, were treated with BzRA's (20 Zol and 3 Esz).
Impaired Vigilance in Patients with Narcolepsy Type 1: A Psychomotor Vigilance Task Study.
Nat Sci Sleep
December 2024
Department of Neurology and Center for Sleep Medicine, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, People's Republic of China.
Purpose: The psychomotor vigilance task (PVT) is one of the main methods to measure sustained vigilance/attention in sleep research. Vigilance is the main factor affecting daytime function in patients with narcolepsy type 1 (NT1). We aimed to quantify the negative effects of sleep-wake disorders on vigilance and investigate potential neural mechanisms.
View Article and Find Full Text PDFThe brain topological alterations in the structural connectome and correlations with clinical characteristics in type 1 narcolepsy.
Neuroimage Clin
November 2024
Department of Diagnostic Radiology, University of Hong Kong, Hong Kong, China. Electronic address:
Objective: To explore topological alterations of white matter (WM) structural connectome, and their associations with clinical characteristics in type 1 narcolepsy (NT1).
Methods: 46 NT1 patients and 34 age- and sex-matched healthy controls were recruited for clinical data and diffusion tensor imaging collection. Using graph theory analysis, the topology metrics of structural connectome, rich club organization, and connectivity properties were compared between two groups.
The Lehigh Valley Health Network narcolepsy cohort: clinical and polysomnographic analysis of 304 cases.
J Clin Sleep Med
November 2024
Lehigh Valley Fleming Neuroscience Institute, Lehigh Valley Health Network, Allentown PA.
Study Objective: We aimed to characterize clinical features, comorbidities and polysomnographic characteristics of a large cohort of patients with narcolepsy.
Methods: We undertook a retrospective chart and polysomnographic review of all patients with a diagnosis of narcolepsy type 1 (NT1) or narcolepsy type 2 (NT2) seen within the Lehigh Valley Health Network between 2000 and 2022.
Results: We found 304 cases with a diagnosis of narcolepsy (52 NT1, 252 NT2), based on , third edition criteria.
Patient experiences of narcolepsy and idiopathic hypersomnia in the Nordics: a patient journey map.
J Sleep Res
October 2024
Department of Clinical Neurophysiology, Rigshospitalet, Danish Center for Sleep Medicine, Copenhagen, Denmark.
Central disorders of hypersomnolence (CDH) are chronic diseases that significantly impact the lives of affected individuals. We aimed to explore the perspectives of individuals with narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH), and the challenges they encounter in their daily lives and within the healthcare systems in the Nordics. Interviews with patients (N = 41) and healthcare professionals (n = 14) and a patient survey (n = 70) were conducted in 2022 in Denmark, Sweden, Finland, and Norway to develop a patient journey map that visualises the patient with CDH journey and provides insights into the difficulties faced by these individuals.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!